Application for regulatory approval of apixaban in European countries to be submitted Bristol-Myers Squibb Firm and Pfizer today announced that the firms are planning to fill out an application for regulatory acceptance of apixaban in Europe for preventing venous thromboembolism after orthopedic surgery in the first fifty % of 2010. The application form will be backed by ADVANCE-2 and ADVANCE-3, two medical trials that evaluated apixaban versus the European dosing routine of enoxaparin for prevention of VTE in individuals undergoing orthopedic surgery. Outcomes of ADVANCE-2 were 1st presented in July 2009 at the 22nd Congress of the International Society on Thrombosis and Haemostasis in Boston. The ADVANCE-3 data will end up being submitted for publication and presentation in 2010 2010.Today in the web edition of the Journal of Clinical Investigation The paper was published. Sparing Sufferers from Debilitating Side Effects According to the American Cancer Society, AML accounts for nearly one-third of all new leukemia cases every year. In 2013, a lot more than 10,000 patients died of AML. AML is certainly a disease where less than 30 % of individuals are cured, said co-senior author Ulrich Steidl, M.D., Ph.D., associate professor of cell biology and of medicine and the Arthur and Diane B.